Shelton Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Shelton Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$544K	Hold	3,229	–	–	0.01%	346
2026 Q1	$425K	Sell	3,229 -127	-4%	-$16.9K	0.01%	401
2025 Q4	$476K	Sell	3,356 -216	-6%	-$31.3K	0.01%	351
2025 Q3	$501K	Hold	3,572	–	–	0.01%	352
2025 Q2	$449K	Sell	3,572 -64	-2%	-$7.34K	0.01%	362
2025 Q1	$402K	Sell	3,636 -175	-5%	-$22.2K	0.01%	376
2024 Q4	$520K	Sell	3,811 -167	-4%	-$20.7K	0.01%	338
2024 Q3	$458K	Sell	3,978 -76	-2%	-$10.4K	0.01%	368
2024 Q2	$558K	Sell	4,054 -96	-2%	-$13.2K	0.02%	322
2024 Q1	$572K	Sell	4,150 -125	-3%	-$17.1K	0.02%	332
2023 Q4	$563K	Sell	4,275 -241	-5%	-$27.7K	0.02%	323
2023 Q3	$508K	Sell	4,516 -245	-5%	-$25.8K	0.02%	321
2023 Q2	$449K	Sell	4,761 -136	-3%	-$13.3K	0.02%	342
2023 Q1	$496K	Hold	4,897	–	–	0.02%	305
2022 Q4	$585K	Sell	4,897 -119	-2%	-$13.9K	0.06%	255
2022 Q3	$533K	Hold	5,016	–	–	0.03%	300
2022 Q2	$489K	Hold	5,016	–	–	0.02%	325
2022 Q1	$470K	Hold	5,016	–	–	0.02%	375
2021 Q4	$427K	Sell	5,016 -192	-4%	-$17.7K	0.02%	419
2021 Q3	$499K	Hold	5,208	–	–	0.02%	357
2021 Q2	$507K	Buy	+5,208	New	+$499K	0.02%	375

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Shelton Capital Management's NBIX Position: Q2 2026 in Review

Shelton Capital Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 3,229 shares worth $544K. The position accounts for 0.01% of the portfolio, ranked #346.

Shelton Capital Management first reported a position in NBIX in Q2 2021 and has held it in 21 quarters since. The position peaked at $585K in Q4 2022. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Shelton Capital Management held 3,229 shares of Neurocrine Biosciences worth $544K as of Q2 2026.
Shelton Capital Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 0.01% of Shelton Capital Management's portfolio in Q2 2026, its #346 holding.
Shelton Capital Management first reported a position in Neurocrine Biosciences in Q2 2021 and has held it in 21 quarters since.
Shelton Capital Management's Neurocrine Biosciences position peaked at $585K in Q4 2022.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Shelton Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.